Published in J Clin Oncol on January 01, 2002
Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc Natl Acad Sci U S A (2005) 2.76
Engineering the perfect (bacterial) cancer therapy. Nat Rev Cancer (2010) 2.70
Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses. Sci Transl Med (2014) 2.69
Monotherapy with a tumor-targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancer. Proc Natl Acad Sci U S A (2007) 2.46
Systemic delivery of Salmonella typhimurium transformed with IDO shRNA enhances intratumoral vector colonization and suppresses tumor growth. Cancer Res (2012) 1.84
Monotherapy with a tumor-targeting mutant of S. typhimurium inhibits liver metastasis in a mouse model of pancreatic cancer. J Surg Res (2009) 1.76
Cancer metastasis directly eradicated by targeted therapy with a modified Salmonella typhimurium. J Cell Biochem (2009) 1.73
Programmable probiotics for detection of cancer in urine. Sci Transl Med (2015) 1.73
Targeted therapy of spinal cord glioma with a genetically modified Salmonella typhimurium. Cell Prolif (2009) 1.55
Tumor invasion of Salmonella enterica serovar Typhimurium is accompanied by strong hemorrhage promoted by TNF-alpha. PLoS One (2009) 1.47
Trg-deficient Salmonella colonize quiescent tumor regions by exclusively penetrating or proliferating. J Control Release (2014) 1.45
Inhibition and eradication of human glioma with tumor-targeting Salmonella typhimurium in an orthotopic nude-mouse model. Cell Cycle (2012) 1.44
Biological gene delivery vehicles: beyond viral vectors. Mol Ther (2009) 1.43
Vessel destruction by tumor-targeting Salmonella typhimurium A1-R is enhanced by high tumor vascularity. Cell Cycle (2010) 1.41
High resolution in vivo bioluminescent imaging for the study of bacterial tumour targeting. PLoS One (2012) 1.36
Tumor-targeting Salmonella typhimurium A1-R decoys quiescent cancer cells to cycle as visualized by FUCCI imaging and become sensitive to chemotherapy. Cell Cycle (2014) 1.30
AAV's anatomy: roadmap for optimizing vectors for translational success. Curr Gene Ther (2010) 1.27
Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth. Proc Natl Acad Sci U S A (2007) 1.24
Tumour-targeted delivery of TRAIL using Salmonella typhimurium enhances breast cancer survival in mice. Br J Cancer (2009) 1.23
Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer. Cancer Immunol Res (2013) 1.15
In tumors Salmonella migrate away from vasculature toward the transition zone and induce apoptosis. Cancer Gene Ther (2011) 1.15
Antitumor effects in mice of the intravenous injection of attenuated Salmonella typhimurium. J Immunother (2002) 1.14
Continuous intravenous administration of live genetically modified salmonella typhimurium in patients with metastatic melanoma. J Immunother (2003) 1.13
Tumor-targeting Salmonella typhimurium A1-R arrests growth of breast-cancer brain metastasis. Oncotarget (2015) 1.12
Tumor-targeting Salmonella typhimurium A1-R in combination with doxorubicin eradicate soft tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) model. Oncotarget (2016) 1.09
Intraperitoneal administration of tumor-targeting Salmonella typhimurium A1-R inhibits disseminated human ovarian cancer and extends survival in nude mice. Oncotarget (2015) 1.05
Bacteria as vectors for gene therapy of cancer. Bioeng Bugs (2011) 1.05
High efficacy of tumor-targeting Salmonella typhimurium A1-R on a doxorubicin- and dactolisib-resistant follicular dendritic-cell sarcoma in a patient-derived orthotopic xenograft PDOX nude mouse model. Oncotarget (2016) 1.03
Motility is critical for effective distribution and accumulation of bacteria in tumor tissue. Integr Biol (Camb) (2011) 1.02
Bacterial therapies: completing the cancer treatment toolbox. Curr Opin Biotechnol (2008) 0.99
Engineering of bacteria for the visualization of targeted delivery of a cytolytic anticancer agent. Mol Ther (2013) 0.99
Inhibition of tumor growth using salmonella expressing Fas ligand. J Natl Cancer Inst (2008) 0.99
Tumor-targeting Salmonella typhimurium A1-R prevents experimental human breast cancer bone metastasis in nude mice. Oncotarget (2014) 0.97
Novel cancer vaccine based on genes of Salmonella pathogenicity island 2. Int J Cancer (2010) 0.97
Targeting tumors with salmonella Typhimurium- potential for therapy. Oncotarget (2010) 0.97
Bacteria and tumours: causative agents or opportunistic inhabitants? Infect Agent Cancer (2013) 0.96
Explicit hypoxia targeting with tumor suppression by creating an "obligate" anaerobic Salmonella Typhimurium strain. Sci Rep (2012) 0.96
Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy. Front Cell Infect Microbiol (2014) 0.96
Efficacy of Tumor-Targeting Salmonella A1-R on a Melanoma Patient-Derived Orthotopic Xenograft (PDOX) Nude-Mouse Model. PLoS One (2016) 0.95
Bacteria in Cancer Therapy: Renaissance of an Old Concept. Int J Microbiol (2016) 0.95
New technologies in developing recombinant attenuated Salmonella vaccine vectors. Microb Pathog (2012) 0.95
Comparison of the selective targeting efficacy of Salmonella typhimurium A1-R and VNP20009 on the Lewis lung carcinoma in nude mice. Oncotarget (2015) 0.93
High-throughput screening for salmonella avirulent mutants that retain targeting of solid tumors. Cancer Res (2010) 0.93
Proteomic screening of anaerobically regulated promoters from Salmonella and its antitumor applications. Mol Cell Proteomics (2011) 0.93
Genetic Circuits in Salmonella typhimurium. ACS Synth Biol (2012) 0.93
Bugging tumors. Cancer Discov (2012) 0.90
Non-invasive 19F MR spectroscopy of 5-fluorocytosine to 5-fluorouracil conversion by recombinant Salmonella in tumours. Br J Cancer (2003) 0.90
Salmonella enterica serovar Typhimurium expressing mutant lipid A with decreased endotoxicity causes maturation of murine dendritic cells. Infect Immun (2003) 0.89
IL-18-producing Salmonella inhibit tumor growth. Cancer Gene Ther (2008) 0.89
In Vivo Gene Expression Dynamics of Tumor-Targeted Bacteria. ACS Synth Biol (2012) 0.89
Identification of tumor-specific Salmonella Typhimurium promoters and their regulatory logic. Nucleic Acids Res (2011) 0.88
Virulence, inflammatory potential, and adaptive immunity induced by Shigella flexneri msbB mutants. Infect Immun (2009) 0.88
Deletion of the Braun lipoprotein-encoding gene and altering the function of lipopolysaccharide attenuate the plague bacterium. Infect Immun (2012) 0.87
Potent and tumor specific: arming bacteria with therapeutic proteins. Ther Deliv (2015) 0.86
Bugs as drugs for cancer. Immunology (2002) 0.86
Improving tumor targeting and therapeutic potential of Salmonella VNP20009 by displaying cell surface CEA-specific antibodies. Vaccine (2007) 0.86
Anti-tumoral effect of the mitochondrial target domain of Noxa delivered by an engineered Salmonella typhimurium. PLoS One (2014) 0.85
Tumor-targeted delivery of biologically active TRAIL protein. Cancer Gene Ther (2010) 0.85
Salmonella as an innovative therapeutic antitumor agent. Int J Mol Sci (2014) 0.85
Salmonella enterica serovars Typhimurium and Typhi as model organisms: revealing paradigm of host-pathogen interactions. Virulence (2012) 0.85
Palmitoylation state impacts induction of innate and acquired immunity by the Salmonella enterica serovar typhimurium msbB mutant. Infect Immun (2011) 0.85
Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors. Cancer Immunol Res (2015) 0.84
Efficiency of conditionally attenuated Salmonella enterica serovar Typhimurium in bacterium-mediated tumor therapy. MBio (2015) 0.84
An enteric pathogen Salmonella enterica serovar Typhimurium suppresses tumor growth by downregulating CD44high and CD4T regulatory (Treg) cell expression in mice: the critical role of lipopolysaccharide and Braun lipoprotein in modulating tumor growth. Cancer Gene Ther (2009) 0.84
Live attenuated S. Typhimurium vaccine with improved safety in immuno-compromised mice. PLoS One (2012) 0.83
Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research. J Gynecol Oncol (2016) 0.83
A bioluminescent transposon reporter-trap identifies tumor-specific microenvironment-induced promoters in Salmonella for conditional bacterial-based tumor therapy. Cancer Discov (2012) 0.83
Blockage of autophagy pathway enhances Salmonella tumor-targeting. Oncotarget (2016) 0.83
Bacterial-mediated knockdown of tumor resistance to an oncolytic virus enhances therapy. Mol Ther (2014) 0.83
Salmonella overcomes tumor immune tolerance by inhibition of tumor indoleamine 2, 3-dioxygenase 1 expression. Oncotarget (2016) 0.82
Attenuated Salmonella typhimurium with IL-2 gene reduces pulmonary metastases in murine osteosarcoma. Clin Orthop Relat Res (2008) 0.82
Escherichia coli Nissle 1917 targets and restrains mouse B16 melanoma and 4T1 breast tumors through expression of azurin protein. Appl Environ Microbiol (2012) 0.82
Safety and immunogenicity of Salmonella typhimurium expressing C-terminal truncated human IL-2 in a murine model. Biologics (2010) 0.81
Salmonella enterica serovar Typhimurium immunotherapy for B-cell lymphoma induces broad anti-tumour immunity with therapeutic effect. Immunology (2014) 0.81
Nosocomial nontyphoidal salmonellosis after antineoplastic chemotherapy: reactivation of asymptomatic colonization? Eur J Clin Microbiol Infect Dis (2004) 0.81
Oral delivery of the Sj23LHD-GST antigen by Salmonella typhimurium type III secretion system protects against Schistosoma japonicum infection in mice. PLoS Negl Trop Dis (2011) 0.81
The concept of immune surveillance against tumors. The first theories. Oncotarget (2016) 0.80
Adjuvant treatment with tumor-targeting Salmonella typhimurium A1-R reduces recurrence and increases survival after liver metastasis resection in an orthotopic nude mouse model. Oncotarget (2015) 0.80
msbB deletion confers acute sensitivity to CO2 in Salmonella enterica serovar Typhimurium that can be suppressed by a loss-of-function mutation in zwf. BMC Microbiol (2009) 0.80
A Salmonella Typhimurium mutant strain capable of RNAi delivery: higher tumor-targeting and lower toxicity. Cancer Biol Ther (2014) 0.80
Synthetic biology expands chemical control of microorganisms. Curr Opin Chem Biol (2015) 0.80
Therapeutic efficacy of tumor-targeting Salmonella typhimurium A1-R on human colorectal cancer liver metastasis in orthotopic nude-mouse models. Oncotarget (2015) 0.80
Programming controlled adhesion of E. coli to target surfaces, cells, and tumors with synthetic adhesins. ACS Synth Biol (2014) 0.79
Tumour-targeting bacteria-based cancer therapies for increased specificity and improved outcome. Microb Biotechnol (2017) 0.79
Phenotypic evolution of therapeutic Salmonella enterica serovar Typhimurium after invasion of TRAMP mouse prostate tumor. MBio (2014) 0.79
A Salmonella nanoparticle mimic overcomes multidrug resistance in tumours. Nat Commun (2016) 0.78
Measuring growth and gene expression dynamics of tumor-targeted S. typhimurium bacteria. J Vis Exp (2013) 0.77
Genetically modified bacteria as a tool to detect microscopic solid tumor masses with triggered release of a recombinant biomarker. Integr Biol (Camb) (2015) 0.77
Inflammation drives thrombosis after Salmonella infection via CLEC-2 on platelets. J Clin Invest (2015) 0.77
Persistent enhancement of bacterial motility increases tumor penetration. Biotechnol Bioeng (2015) 0.77
Myristoylation negative msbB-mutants of probiotic E. coli Nissle 1917 retain tumor specific colonization properties but show less side effects in immunocompetent mice. Bioeng Bugs (2009) 0.77
RGD Peptide Cell-Surface Display Enhances the Targeting and Therapeutic Efficacy of Attenuated Salmonella-mediated Cancer Therapy. Theranostics (2016) 0.77
Toxicology and efficacy of tumor-targeting Salmonella typhimurium A1-R compared to VNP 20009 in a syngeneic mouse tumor model in immunocompetent mice. Oncotarget (2017) 0.76
Improving cancer therapies by targeting the physical and chemical hallmarks of the tumor microenvironment. Cancer Lett (2015) 0.76
Strains, Mechanism, and Perspective: Salmonella-Based Cancer Therapy. Int J Microbiol (2016) 0.76
Bacterial immunotherapy of gastrointestinal tumors. Langenbecks Arch Surg (2011) 0.76
Solid tumors provide niche-specific conditions that lead to preferential growth of Salmonella. Oncotarget (2016) 0.76
Bacteria as tumor therapeutics? Bioeng Bugs (2010) 0.76
Therapy of solid tumors using probiotic Symbioflor-2: restraints and potential. Oncotarget (2016) 0.76
Vasculature Disruption Enhances Bacterial Targeting of Autochthonous Tumors. J Cancer (2015) 0.76
Proinflammatory cytokines. Chest (2000) 5.89
Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo. Nat Biotechnol (1999) 3.97
Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res (1997) 3.45
Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium. J Infect Dis (2000) 2.63
Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. Chest (1997) 2.52
Regulation of the proinflammatory effects of Fas ligand (CD95L). Science (1998) 2.43
A lethal role for lipid A in Salmonella infections. Mol Microbiol (1998) 2.30
Induction of tolerance to lipopolysaccharide (LPS)-D-galactosamine lethality by pretreatment with LPS is mediated by macrophages. Infect Immun (1988) 2.23
Salmonella-induced caspase-2 activation in macrophages: a novel mechanism in pathogen-mediated apoptosis. J Exp Med (2000) 1.79
Salmonella focal intracranial infections: review of the world literature (1884-1984) and report of an unusual case. Rev Infect Dis (1986) 1.61
Expression of human IL-1 beta in Salmonella typhimurium. A model system for the delivery of recombinant therapeutic proteins in vivo. J Immunol (1992) 1.31
Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer. Eur J Cancer (1996) 1.26
Abscess formation in a pheochromocytoma; report of a case due to Salmonella typhimurium. N Engl J Med (1954) 1.26
Salmonellosis--a review of some unusual aspects. N Engl J Med (1960) 1.14
Antitumor mechanisms of attenuated Salmonella typhimurium containing the gene for human interleukin-2: a novel antitumor agent? J Pediatr Surg (1997) 1.13
Abscess caused by Salmonella enteritidis within a glioblastoma multiforme. J Infect (1987) 1.02
Salmonellosis: an unusual complication of hepatocellular carcinoma. Scand J Gastroenterol (1997) 0.95
Infection of a secondary carcinoma by Salmonella montevideo. Br Med J (1952) 0.95
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 14.59
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol (2005) 12.88
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 11.08
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol (2008) 10.13
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol (2005) 9.72
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood (2009) 9.24
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol (2011) 9.19
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther (2010) 9.13
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res (2011) 9.03
A mosaic activating mutation in AKT1 associated with the Proteus syndrome. N Engl J Med (2011) 8.26
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med (2005) 8.13
Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol (2006) 7.76
A human memory T cell subset with stem cell-like properties. Nat Med (2011) 7.47
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol (2006) 7.40
Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39
Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet (2011) 7.31
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood (2010) 7.25
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res (2006) 7.09
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest (2005) 7.01
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet (2012) 7.00
CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol (2005) 6.95
Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science (2014) 6.88
Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood (2008) 6.81
Tracking a hospital outbreak of carbapenem-resistant Klebsiella pneumoniae with whole-genome sequencing. Sci Transl Med (2012) 6.63
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood (2009) 6.17
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med (2013) 6.01
Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol (2002) 5.75